

conditions is met: 5 is not arginine, 9 is not arginine, 10 is not lysine, 11 is not serine, or 13 is not phenylalanine;

2 is selected from the group consisting of alanine, valine, isoleucine, leucine, phenylalanine, methionine, tryptophan or tyrosine;

3 is selected from the group consisting of glutamine, asparagine, serine or threonine;

C1  
Cont 4 is selected from the group consisting of glycine, alanine, valine, isoleucine, leucine phenylalanine, methionine, tryptophan or tyrosine;

5 is selected from the group consisting of alanine, threonine, glutamine, asparagine or serine; and 5 may also be arginine or lysine when at least one of the following conditions is met: 1 is not arginine, 9 is not arginine, 10 is not lysine, 11 is not serine, or 13 is not phenylalanine;

6 is tryptophan or phenylalanine;

7 is lysine or arginine;

8 is selected from the group consisting of alanine, valine, isoleucine, leucine, phenylalanine or tyrosine;

9 is selected from the group consisting of alanine, threonine, glutamine, asparagine or serine; and 9 may also be arginine or lysine when at least one of the following conditions is met: 1 is not arginine, 5 is not arginine, 10 is not lysine, 11 is not serine, or 13 is not phenylalanine;

10 is selected from the group consisting of alanine, valine, isoleucine, leucine, phenylalanine, methionine, tryptophan or tyrosine; and 10 may also be arginine or lysine when at least one of the following conditions is met: 1 is not arginine, 5 is not arginine, 9 is not arginine, 11 is not serine, or 13 is not phenylalanine;

11 is alanine or valine; and 11 may also be serine when at least one of the

following conditions is met: 1 is not arginine, 5 is not arginine, 9 is not arginine, 10 is not lysine, or 13 is not phenylalanine; and 11 may also be threonine, glutamine, asparagine, lysine or arginine when 10 is not lysine;

12 is selected from the group consisting of phenylalanine, tryptophan or tyrosine;

13 is selected from the group consisting of alanine, threonine, glutamine, asparagine or serine; and 13 may also be phenylalanine, arginine or lysine when at least one of the following conditions is met: 1 is not arginine, 5 is not arginine, 9 is not arginine, 10 is not lysine or 11 is not serine; and 13 may also be glycine if 14 is lysine or arginine;

14 is selected from the group consisting of lysine, arginine or alanine; and 14 may also be valine, isoleucine, leucine, phenylalanine, methionine, tryptophan or tyrosine, if 13 is not phenylalanine; and

Y is a linear chain consisting of zero to four amino acids.

38. An LPS-binding and –neutralizing peptide according to claim 37, wherein said peptide constitutes the N-terminal region of a larger polypeptide.

39. An LPS-binding and –neutralizing peptide according to claim 37, wherein said peptide constitutes the C-terminal region of a larger polypeptide.

40. An LPS-binding and –neutralizing peptide according to claim 37, wherein said peptide is inserted into a larger polypeptide.

41. An LPS-binding and –neutralizing peptide according to claim 37, wherein at least one amino acid of said peptide is substituted by a non-natural homologous amino acid.

42. An LPS-binding and –neutralizing peptide according to claim 38, wherein the N-terminus is modified by acetylation or succinylation.

43. An LPS-binding and –neutralizing peptide according to claim 37, wherein the C-terminus is a -OH, -COOH or -CONH<sub>2</sub> group.

44. An LPS-binding and –neutralizing peptide according to claim 39, wherein the C-terminus is a -OH, -COOH or -CONH<sub>2</sub> group.

45. An LPS-binding and –neutralizing peptide according to claim 37, wherein said peptide is constrained to adopt a cyclic conformation by an intramolecular disulfide or amide bond.

46. An LPS-binding and –neutralizing peptide according to claim 41, wherein said peptide is constrained to adopt a cyclic conformation by an intramolecular disulfide or amide bond.

47. An LPS-binding and –neutralizing peptide according to claim 37, wherein the chain backbone of said peptide is substituted by backbone-mimetic organic entities.

48. An LPS-binding and –neutralizing peptide according to claim 41, wherein the chain backbone of said peptide is substituted by backbone-mimetic organic entities.

49. An LPS-binding and –neutralizing peptide according to claim 37, wherein at least one

C1  
Cont

amino acid of said peptide is substituted by alkylation using chemical or enzymatic methods.

50. An LPS-binding and –neutralizing peptide according to claim 37, wherein at least one amino acid of said peptide is glycosylated using chemical or enzymatic methods.

51. An LPS-binding and –neutralizing peptide according to claim 37, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

52. An LPS-binding and –neutralizing peptide according to claim 38, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

53. An LPS-binding and –neutralizing peptide according to claim 39, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

54. An LPS-binding and –neutralizing peptide according to claim 40, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

55. An LPS-binding and –neutralizing peptide according to claim 41, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

56. An LPS-binding and –neutralizing peptide according to claim 42, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

57. An LPS-binding and –neutralizing peptide according to claim 43, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

*CI*  
*Chait*  
58. An LPS-binding and –neutralizing peptide according to claim 44, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

59. An LPS-binding and –neutralizing peptide according to claim 45, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.


60. An LPS-binding and –neutralizing peptide according to claim 46, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

61. An LPS-binding and –neutralizing peptide according to claim 47, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

62. An LPS-binding and –neutralizing peptide according to claim 48, wherein said

peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

63. LPS-binding and –neutralizing peptide according to claim 49, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

 64. LPS-binding and –neutralizing peptide according to claim 50, wherein said peptide further comprises a label selected from the group consisting of biotin, radioisotopes, enzymes, colloidal metals or fluorescent, chemiluminescent, or phosphorescent compounds.

65. A linear polypeptide chain containing two or more repeats of an LPS-binding and –neutralizing peptide according to claim 37, wherein said repeats of the peptide are connected by 12-25 amino acid linkers, rich in glycine, alanine, proline or serine residues.

66. A linear polypeptide chain containing a combination of two or more LPS-binding and –neutralizing peptides according to claim 37, wherein said combination of the peptides is connected by 12-25 amino acid linkers, rich in glycine, alanine, proline or serine residues.


67. A linear polypeptide chain containing two or more repeats of an LPS-binding and –neutralizing peptide according to claim 41, wherein said repeats of the peptide are connected by 12-25 amino acid linkers, rich in glycine, alanine, proline or serine residues.

68. A linear polypeptide chain containing a combination of two or more LPS-binding and –neutralizing peptides according to claim 41, wherein said combination of the peptides is

connected by 12-25 amino acid linkers, rich in glycine, alanine, proline or serine residues.

69. An arrangement of three or more LPS-binding and –neutralizing peptides according to claim 37, wherein said peptides are linked by their C-terminus to a lysine core structure.

70. An arrangement of three or more LPS-binding and –neutralizing peptides according to claim 41, wherein said peptides are linked by their C-terminus to a lysine core structure.

 71. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 37 and a pharmaceutically acceptable diluent, carrier or adjuvant.

72. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 38 and a pharmaceutically acceptable diluent, carrier or adjuvant.

73. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 39 and a pharmaceutically acceptable diluent, carrier or adjuvant.

74. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 40 and a pharmaceutically acceptable diluent, carrier or adjuvant.

75. A pharmaceutical composition comprising an effective amount of an LPS-binding and

–neutralizing peptide according to claim 41 and a pharmaceutically acceptable diluent, carrier or adjuvant.

76. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 42 and a pharmaceutically acceptable diluent, carrier or adjuvant.

C1  
C2

77. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 43 and a pharmaceutically acceptable diluent, carrier or adjuvant.

78. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 44 and a pharmaceutically acceptable diluent, carrier or adjuvant.

79. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 45 and a pharmaceutically acceptable diluent, carrier or adjuvant.

80. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 46 and a pharmaceutically acceptable diluent, carrier or adjuvant.

81. A pharmaceutical composition comprising an effective amount of an LPS-binding and –neutralizing peptide according to claim 47 and a pharmaceutically acceptable diluent, carrier



or adjuvant.

82. A pharmaceutical composition comprising an effective amount of an LPS-binding and -neutralizing peptide according to claim 48 and a pharmaceutically acceptable diluent, carrier or adjuvant.

C1  
Cove  
83. A pharmaceutical composition comprising an effective amount of an LPS-binding and -neutralizing peptide according to claim 49 and a pharmaceutically acceptable diluent, carrier or adjuvant.

84. A pharmaceutical composition comprising an effective amount of an LPS-binding and -neutralizing peptide according to claim 50 and a pharmaceutically acceptable diluent, carrier or adjuvant.

---